A Phase 3, Randomized, Double-Blind, Controlled Study of the Efficacy & Safety of VX-445 (32 weeks)


Clinical Trial

Offered by: Nemours
Location: Orlando, Fla. and Jacksonville, Fla.

What is the trial about?

The purpose of the study is to learn more about the effectiveness and safety of VX-445 used in combination with TEZ (tezacaftor) and IVA (ivacaftor) in patients with cystic fibrosis who have both a F508 deletion and a MF mutation (F/MF).

Who can participate?

Individuals, 12 years of age or older, who have a confirmed diagnosis of Cystic Fibrosis and have both: a F508 deletion and a MF mutation (F/MF).

What is involved?

Participation could last approximately 32 weeks. This includes a screening period that will last up to 4 weeks, a 24-week treatment period and a follow-up 4 weeks after the last dose of the Study Drug.

There will be up to nine (9) clinic visits and one (1) telephone call, including:

  • Blood draws: The total amount of blood that will be taken during this study will be about 167.5mL (34 teaspoons). Total of nine (9) scheduled blood draws.
  • ECGs: Total of nine (9) scheduled ECGs.
  • Spirometry (PFT): Total of nine (9) scheduled PFTs.
  • Sweat Chloride Tests: Total of six (6) Sweat Chloride Tests.
  • Eye Exams: Up to three (3) eye exams.

Contact Nemours Clinical Trials

Trial Name: A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of VX-445

Contact Information

(800) 354-5690
ClinicalTrials@nemours.org